Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ZL-1201

Monoclonal antibody · Immune activation, directed at CD47 · developed by Zai Lab Co.

Phase 1 Most advanced trial (none active)
ZLAB Developer
1 Registered trials

What is ZL-1201?

ZL-1201 is a humanized IgG4 monoclonal antibody that binds CD47 on tumor cells and blocks its interaction with SIRPa on phagocytic cells. This relieves inhibition of macrophage activation and enables phagocytosis of cancer cells. It is studied in advanced cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Monotherapy
Drug type
Monoclonal antibody
Targets
CD47, signal regulatory protein alpha (SIRPA) (binding partner it blocks), calreticulin (CALR) (binding partner it blocks), LRP-1 (binding partner it blocks)
Mechanism
Immune activation, directed at CD47
Pathways
CD47/SIRPa signaling, macrophage activation, macrophage phagocytosis of tumor cells
Therapy area
Oncology
Developer
Zai Lab Co., Ltd. (ZLAB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04257617 Phase 1 Advanced Cancer Completed ZLAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Cancer

Other drugs acting on CD47

More from Zai Lab Co.

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the ZLAB page.

Follow ZLAB, the company behind ZL-1201

See ZLAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ZLAB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.